Review
Biochemistry & Molecular Biology
Yang Zhou, Tiffany Husman, Xinjian Cen, Tasha Tsao, James Brown, Aarushi Bajpai, Miao Li, Kuangyi Zhou, Lili Yang
Summary: Cell-based cancer immunotherapy, especially using IL-15 as an immunostimulatory cytokine, has shown great potential in improving the therapeutic efficacy of current treatments. This review highlights the biology of IL-15, studies on its administration and its derivatives, and the advantages and challenges of incorporating IL-15 in cell-based immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Jose Saura-Esteller, Milon De Jong, Lisa A. King, Erik Ensing, Benjamin Winograd, Tanja D. De Gruijl, Paul W. H. I. Parren, Hans J. Van Der Vliet
Summary: Gamma delta T-cells can recognize and kill transformed cells independently of HLA-antigen presentation, making them a promising effector cell compartment for cancer immunotherapy. Current research is focused on the V delta 1 and V delta 2 T-cell subtypes, with V delta 1 enriched in tissues and V delta 2 enriched in circulation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Ping Xiao, Jue Wang, Lei Fang, Zitong Zhao, Xiangshi Sun, Xiaochen Liu, Haiqiang Cao, Pengcheng Zhang, Dangge Wang, Yaping Li
Summary: The combination of neoantigen-loaded nanovaccines and adoptive dendritic cell transfer enhances personalized immunity by facilitating immune cell access to lymph nodes and inhibiting tumor growth.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Review
Biochemistry & Molecular Biology
Audrey Page, Julie Hubert, Floriane Fusil, Francois-Loic Cosset
Summary: Immunotherapy strategies utilizing B cells have shown promising results in reducing tumor growth and enhancing antitumoral immune responses. By modifying B cells through various methods such as increasing antigen presentation or antibody secretion, their therapeutic role can be enhanced for potential cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Alessia Volpe, Prasad S. Adusumilli, Heiko Schoder, Vladimir Ponomarev
Summary: Cellular immunotherapies have shown success in treating diseases like cancer, but their effectiveness varies among patients and tumor types. Understanding the complexity of cellular immunotherapies and identifying factors that affect treatment response is crucial. Non-invasive molecular imaging can play a significant role in evaluating treatment outcomes and predicting therapeutic responses. This review outlines the strategies for molecular imaging of cellular immunotherapies and discusses their current role in clinical practice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mork, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jorgensen, Lene Buhl Riis, Christina Westmose Yde, Ozcan Met, Marco Donia, Inge Marie Svane
Summary: This study demonstrated high success rates of TIL expansion and tumor regressions in multiple solid cancer types when combining TIL ACT with CPIs. In vitro tumor reactivity was positively associated with treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Rodrigo C. C. De Marco, Hector J. J. Monzo, Paivi M. Ojala
Summary: With the continuous advancements in immunotherapy and precision medicine, adoptive cell therapy (ACT) has emerged as a new treatment approach in oncology. Chimeric antigen receptor (CAR) T cells, genetically modified lymphocytes, have shown promising results in targeting and killing cancer cells. Commercialization of CAR T cell therapy has paved the way for future bright developments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Celine Man Ying Li, Yoko Tomita, Bimala Dhakal, Runhao Li, Jun Li, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Kevin Aaron Fenix
Summary: This review systematically assessed the efficacy of cytokine-induced killer cell (CIK) therapy for colorectal cancer (CRC) treatment and found that CIK therapy improved overall survival, progression-free survival, and overall response rate without increasing toxicity. Further investigation into CIK therapy for CRC treatment is warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Marion Arnaud, Sara Bobisse, Johanna Chiffelle, Alexandre Harari
Summary: Mutation-derived neoantigens have become attractive targets for cancer immunotherapy. The field of adoptive T cell transfer (ACT) therapy has been reshaped by tumor neoantigens, leading to the genetic engineering of T cells with neoantigen-specific T cell receptors (TCRs). Challenges remain in identifying neoantigen-reactive TCRs and adjusting the process to fit clinical timelines, along with the critical importance of the state of recipient T cells for TCR transduction in affecting TCR-ACT efficacy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Sainiteesh Maddineni, John L. Silberstein, John B. Sunwoo
Summary: This article reviews multiple approaches for allogeneic NK cell therapy and discusses the advantages and disadvantages of each method. In recent years, NK cells have become increasingly important players in the immune response against cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, David Spriggs, Richard J. O'Reilly, Roisin E. O'Cearbhaill
Summary: This study demonstrated the safety of using WT1-sensitized T cells for treating patients with recurrent ovarian, primary peritoneal, and fallopian tube carcinomas, but no therapeutic activity was observed at the low doses evaluated.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan, Nashmin Fayazi
Summary: CAR T cell therapy has shown great potential in treating hematologic malignancies, but faces challenges in treating solid tumors, including treatment-related toxicity and specificity. In order to enhance the specificity and overcome immunosuppression, strategies to establish a balance between toxicity and activity of CAR T cells are essential for optimizing efficacy.
Article
Chemistry, Multidisciplinary
Naishun Liao, Lichao Su, Youshi Zheng, Bixing Zhao, Ming Wu, Da Zhang, Huanghao Yang, Xiaolong Liu, Jibin Song
Summary: The study introduces a novel ratiometric NIR-II fluorescence imaging strategy to track and visualize NK cell viability in vivo, demonstrating that co-treatment with IL-2, IL-15, and IL-21 can enhance NK cell viability and improve immunotherapy for hepatocellular carcinoma. This approach allows for longitudinal and quantitative monitoring of NK cell viability in NK cell-based immunotherapy.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Article
Engineering, Biomedical
Qi Chen, Lizhen He, Xiaoying Li, Ligeng Xu, Tianfeng Chen
Summary: The study focuses on designing ruthenium (Ru) polypyridyl complexes to enhance NK cells immunotherapy. The RuPOP complex effectively regulates immune suppressors and target proteins in tumor cells, increasing their sensitivity to NK cells. The combination treatment induces ROS generation, activates apoptosis-related receptors, and enhances interactions between NK and tumor cells, leading to caspase 3-dependent apoptosis. Additionally, the treatment boosts NK cell infiltration and reduces MDSC's protumoral capability. This study provides insights for enhancing NK cells immunotherapy and developing more effective clinical treatment options.
Review
Immunology
Maria Velasco-de Andres, Guillermo Munoz-Sanchez, Laura Carrillo-Serradell, Maria del Mar Gutierrez-Hernandez, Cristina Catala, Marcos Isamat, Francisco Lozano
Summary: Adoptive cell transfer (ACT) therapies, especially those based on chimeric antigen receptor (CAR) technology, have gained significant attention in the field of immunotherapy. CAR-based ACT has shown successful results in treating hematological malignancies and has the potential to be effective in other tumors as well as immune-mediated disorders. This review discusses the results and limitations of preclinical and clinical studies in areas such as infection, allergy, autoimmunity, transplantation, and fibrotic repair.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2023)